FOLLOW US

In a move set to reshape the oncology market, Jazz Pharmaceuticals announced Wednesday its plans to acquire Chimerix in a $935 million all-cash deal. The acquisition, orchestrated by three powerhouse law firms, will further strengthen Jazz’s foothold in cancer treatment, particularly in the high-stakes battle against rare and aggressive brain tumors.

Big Premium, Bigger Potential

Jazz will launch an all-cash tender offer of $8.55 per share for Chimerix’s outstanding stock—a staggering 72% premium over Chimerix’s closing price on Tuesday. The deal signals Jazz’s aggressive push into high-value oncology assets, banking on Chimerix’s lead candidate, dordaviprone, a groundbreaking therapy for the deadly H3 K27M-mutant diffuse glioma.

With no current FDA-approved treatments for this rare pediatric and young adult brain cancer, dordaviprone has the potential to redefine the standard of care.

Legal Powerhouses Behind the Deal

Jazz has enlisted legal heavyweights from Wachtell, Lipton, Rosen & Katz to navigate the acquisition, while Chimerix is advised by Skadden, Arps, Slate, Meagher & Flom LLP and Cooley LLP. The involvement of these top-tier firms underscores the complexity and high stakes of the transaction.

A Drug That Could Change Everything

Dordaviprone, a first-in-class small molecule therapy, is poised to fill a massive treatment gap. Radiation remains the primary option for patients with H3 K27M-mutant diffuse glioma, but dordaviprone could offer a much-needed breakthrough.

"If approved, dordaviprone has the potential to rapidly become the standard of care for a rare oncology disease," said Jazz Chairman and CEO Bruce Cozadd. "We are eager to integrate it into our pipeline and bring this innovative treatment to patients who desperately need new options."

The FDA has already granted priority review to dordaviprone’s New Drug Application (NDA), setting a Prescription Drug User Fee Act (PDUFA) action date for August 15. If given the green light, the drug could see a rapid U.S. commercial launch by late 2025.

Chimerix CEO: "A Global Opportunity"

For Chimerix, the acquisition represents years of cutting-edge research culminating in a global commercialization opportunity.

"We are excited to partner with Jazz Pharmaceuticals, a company with the scale and expertise to bring dordaviprone to more patients worldwide," said Chimerix President and CEO Mike Andriole. "This deal is the culmination of years of scientific dedication, and it delivers both value to our shareholders and hope to patients."

What’s Next?

Jazz intends to finance the acquisition with its existing cash reserves and investments, with an expected closing in Q2 2025, pending regulatory approvals and customary closing conditions. Once finalized, Jazz will leverage its development and commercial capabilities to accelerate dordaviprone’s clinical trial progress and market launch.

With the finish line in sight, all eyes are on the FDA’s decision—a potential game-changer in the fight against aggressive brain tumors.